Applying Botulinum toxin type A to the “11s” (ie, the lines between our brows) increased patient satisfaction with the procedure by 28%, according to the patient-reported outcomes survey FACE-Q.

The newly developed survey comprises 63 questions asking participating patients to evaluate their overall appearance, age appearance, and the appearance of cheeks, nasolabial folds, lower face and jawline, chin, and neck.

A study evaluating patient perceptions of their Botox treatments using the survey was published recently in Aesthetic Surgery Journal, the official publication of the American Society for Aesthetic Plastic Surgery (ASAPS).

“The results of this study are not surprising and validate what we’ve suspected for quite some time,” says ASAPS president Daniel C. Mills, MD, in a media release from ASAPS. “It’s a quick nonsurgical fix that packs a powerful punch, and this new study reaffirms the efficacy of botulinum toxin type A and the satisfaction it brings to patients.”

The study’s authors examined 57 female patients who completed the FACE-Q survey, the release explains. After the baseline survey, the patients received injections of one brand of botulinum toxin type A, (Botox, Dysport, or Xeomin) in the region between the brows. Two weeks post-injection, the patients completed the FACE-Q survey again. The percentage changes in patient responses from the first to second surveys were assessed to determine how the injections affected patient satisfaction with their facial appearance.

“This indicates that patients’ satisfaction with their overall facial appearance was statistically significantly greater after receiving the injections, and certainly accounts for the continued success of neurotoxin popularity to reduce the signs of aging,” states Dr Ivona Percec, the study’s senior author, in the release.

[Source(s): ASAPS, PR Newswire]